Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

555 results about "Cellular death" patented technology

Cell death. Thesaurus. Definitions of cell death. 1. a type of cell death in which the cell uses specialized cellular machinery to kill itself; a cell suicide mechanism that enables metazoans to control cell number and eliminate cells that threaten the animal's survival.

Blood-brain barrier disruption using reversible or irreversible electroporation

The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. Included is a method of treating tissue with electrical energy, the method comprising: delivering electrical energy to tissue using one or more electroporation devices comprising one or more electrodes; and cooling the tissue, surrounding tissue, one or more of the electrodes, or one or more of the electroporation devices to minimize heating. In embodiments, the invention can be used to treat solid tumors, such as brain tumors, and in some embodiments, exemplary methods rely on non-thermal irreversible electroporation (IRE) to cause cell death in treated tumors.
Owner:VIRGINIA TECH INTELLECTUAL PROPERTIES INC

Controlling Citrus Huanglongbing (HLB) by Mitigating Cell Death of the Phloem Tissues Caused by Candidatus Liberibacter Asiaticus (CLas) By Suppressing Reactive Oxygen Species (ROS)

It is presented that citrus Huanglongbing (HLB), caused by phloem-colonizing Candidatus Liberibacter asiaticus (CLas), is an immune-mediated disease. CLas infection of Citrus sinensis stimulated systemic and chronic immune response in the phloem tissues including reactive oxygen species (ROS) production. Methods and compositions for transfecting plants and regenerating plants to express antioxidant enzymes or shut down genes to reduce adverse effects of CLas infection are provided.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Methods and systems for inducing apoptosis of adipose cells

PendingUS20250135004A1Organic active ingredientsDNA/RNA fragmentationAdipocyte apoptosisMedicine
Methods and systems for inducing apoptosis of adipose cells are disclosed herein. In some embodiments, the method comprises identifying a target area comprising the adipose cells and injecting a therapeutic agent at the target area. Injecting the therapeutic agent can inhibit a protein kinase B (Akt) pathway of the adipose cell, induce a proinflammatory response of adipose cells at the target area, and / or initiate lipolysis / cell death of the adipose cells at the target area. In doing so, a volume of the adipose cells at the target area can be reduced.
Owner:CRYOSA INC

Tricyclic compound, and preparation method therefor and use thereof

A tricyclic compound, and a preparation method therefor and the use thereof. The present invention relates to a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, genetic disorders, hormone-related diseases, metabolic disorders, organ-transplantation-related diseases, immunodeficiency disorders, destructive bone diseases, proliferative disorders, infectious diseases, cell-death-related conditions and cardiovascular diseases. Each substituent in general formula (I) is as defined in the description.
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD

Methods and systems for inducing apoptosis of adipose cells

PendingUS20250134915A1Organic active ingredientsDNA/RNA fragmentationAdipocyte apoptosisMedicine
Methods and systems for inducing apoptosis of adipose cells are disclosed herein. In some embodiments, the method comprises identifying a target area comprising the adipose cells and injecting a therapeutic agent at the target area. Injecting the therapeutic agent can inhibit a protein kinase B (Akt) pathway of the adipose cell, induce a proinflammatory response of adipose cells at the target area, and / or initiate lipolysis / cell death of the adipose cells at the target area. In doing so, a volume of the adipose cells at the target area can be reduced.
Owner:CRYOSA INC

Anti-human CD89 antibodies and uses thereof

The invention discloses an antibody that can bind an extra-cellular part of human CD89 (human FcαRI) on human CD89 expressing cells that prevents binding of human IgA to human CD89 when the antibody is bound to said cells and that induces less cell death in said human CD89 expressing cells when compared to the antibody MIP8a. The invention also disclosed the use of such antibodies in combating certain diseases.
Owner:JJP BIOLOGICS SP ZOO

Bionic ferroptosis nanoparticles loaded with superparamagnetic iron oxide nanoparticles as well as preparation method and application of bionic ferroptosis nanoparticles loaded with superparamagnetic iron oxide nanoparticles

The invention relates to bionic ferroptosis nanoparticles loaded with superparamagnetic iron oxide nanoparticles as well as a preparation method and application of the bionic ferroptosis nanoparticles. The biomimetic ferroptosis nano-particles are obtained by loading the superparamagnetic iron oxide nano-particles packaged by the biomimetic platelet membrane, Erastin and lactate oxidase together, and are used for guiding magnetic resonance imaging and inducing tumor cell ferroptosis. According to the method, ferroptosis is induced through Erastin, lactic acid is removed through lactate oxidase, and ferroptosis is enhanced. In addition, lactic acid is oxidized to generate hydrogen peroxide, the hydrogen peroxide is converted into cytotoxic hydroxyl radicals, and cell death is further accelerated. When the PM-ESLNP is combined with an alphaPD-L1 immunotherapy, the PM-ESLNP obviously inhibits tumor growth and metastasis in a liver cancer mouse model, and the result exceeds that of a single immunotherapy. In addition, the superparamagnetic nanoparticles in the PM-coated ESLNP can be used for carrying out real-time MRI (Magnetic Resonance Imaging) monitoring on the treatment effect. According to the invention, a groundbreaking MRI guiding method is introduced, so that ferroptosis of tumors can be enhanced and tumor immunotherapy can be synergistically improved.
Owner:LISHUI CENT HOSPITAL

Compositions and methods for treating cancer by targeting endothelial cells having upregulated expression of transmembrane molecules

The technology described herein is directed to targeting molecules that bind to one or more transmembrane molecules expressed in tumor vascular endothelial cells and that are capable of targeting an agent that induces cell death, for example, immunogenic or non-immunogenic cancer cell death. In another aspect, described herein are methods of treating a subject having cancer comprising administering said targeting molecules and agents, and, in certain embodiments, enhancing the immunogenic response to the cancer, for example, by enhancing intratumoral infiltration of T cells.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Cell vesicle co-delivery system, anti-tumor drug and application

The invention belongs to the field of tumor drug research, and particularly relates to a cell vesicle co-delivery system, an anti-tumor drug and application. The cell vesicle-like co-delivery system is constructed according to the following steps: co-transfecting a recombinant expression vector of tumor targeting protein or targeting peptide and a recombinant plasmid of circRNA of effector molecules related to pyroptosis to a tool cell, and collecting to obtain the cell vesicle-like co-delivery system, a recombinant expression vector of the tumor targeting protein or the targeting peptide contains a DNA sequence for coding MCP protein, and a recombinant plasmid of circRNA of an effector molecule related to pyroptosis contains a DNA sequence for coding MS2 protein. According to the cell vesicle co-delivery system provided by the invention, tumor cell death is directly induced by delivering the cell death related effector molecule RNA through the cell vesicles, the killing efficiency is high, the side effect is relatively small, and the problems of mass production and drug loading can be solved.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Wheat stem rot regulatory gene Tatrx-m, encoding protein thereof, recombinant vector and application of wheat stem rot regulatory gene Tatrx-m

The invention relates to a wheat stem rot regulatory gene Tatrx-m, and an encoding protein, a recombinant vector and an application of the wheat stem rot regulatory gene Tatrx-m. The genomic sequence of the gene is SEQ ID NO.1, the CDS sequence of the gene is SEQ ID NO.2, and thioredoxin shown as SEQ ID NO.3 is encoded. The invention further provides a specific primer pair used for gene identification, a silent vector (Tatrx-m-VIGS) and an overexpression vector (LGY-OE3-Tatrx-m) are constructed, and the function of the primer pair is verified through a virus-induced gene silencing (VIGS) technology and agrobacterium-mediated transformation of wheat. Experiments show that silence of Tatrx-m results in significant reduction of wheat stem rot resistance, and overexpression of the gene can improve resistance. Based on hypha quantification, DAB staining, H2O2 content and cell death analysis, Tatrx-m is revealed to enhance wheat resistance by regulating active oxygen removal and cell wall strengthening pathways. The gene TaTrx-m has the positive regulation effect in wheat stem rot for the first time, can be applied to disease-resistant molecular marker development, gene editing and transgenic breeding, provides core genetic resources for disease-resistant variety breeding, and has theoretical and application values.
Owner:HENAN AGRICULTURAL UNIVERSITY

Copper death inducer independent of copper ion carrier and application of copper death inducer

The invention provides a copper death inducer independent of a copper ion carrier and application of the copper death inducer. According to the novel copper death inducer, copper ions do not need to be additionally added in an extracellular environment. Experimental results show that under the coexistence of the ferroptosis inducer and the ferroptosis inhibitor, the treatment of the glutathione inhibitor can induce the cells to generate obvious death. The cell death can be inhibited by a specific inhibitor TTM of copper death, and has typical forms and biochemical characteristics of copper death, namely oligomerization of DLAT protein. Because copper death and copper death drugs have basic and clinical application prospects, the provided new inducer combination will provide a new small molecule induction strategy and research and application directions for copper death related research.
Owner:JINAN UNIVERSITY

Gamma delta t cell compositions and methods of use

The present disclosure provides genetically modified iPSC-derived γδT cells and their precursors. A double genomic disruption in the suppressor of cytokine signaling 1 (SOCS1) gene and the cytokine-inducible sh2-containing protein (CISH) gene are provided, as is a triple genomic disruption in genes for SOCS1, CISH, and Bcl-2 interacting mediator of cell death (BIM), as is a quadruple genomic disruption in genes for SOCS1, CISH, BIM, and cell surface death receptor (FAS), as is a quintuple genomic disruption in genes for SOCS1, CISH, BIM, β-2-Microglobulin (B2M), and class II transactivator (CITTA), as is a sextuple genomic disruption in genes for SOCS1, CISH, BIM, B2M, CITTA, and FAS. Also provided is genetically modified iPSC-derived γδT cells and their precursors with improved proliferation and tumor killing activity. Also provided are genetically modified iPSC-derived γδT cells and their precursors further comprising CD19 CAR. The present disclosure further provides methods making and using such cells, as well as gene editing systems.
Owner:BEONE MEDICINES I GMBH

Device and system for performing electric field treatment on digestive tract

The invention discloses a device and system for conducting electric field treatment on the digestive tract, the device for conducting electric field treatment on the digestive tract comprises a slender catheter, a supporting body located at the far end of the catheter, an electrode array film and a pulse generator, the electrode array film and the pulse generator are arranged on the supporting body, and the output end of the pulse generator is coupled with an electrode pair on the electrode array film. A sequence pulse wave output by the pulse generator comprises a plurality of groups of nanosecond pulse strings, and the time interval between the adjacent nanosecond pulse strings is 1us-10000 us; the nanosecond pulse string is composed of a plurality of nanosecond pulse pairs, and the time interval between every two adjacent nanosecond pulse pairs ranges from 50 ns to 10000 ns; the nanosecond pulse pair comprises positive pulses and negative pulses which appear alternately, the pulse width of the positive pulses and the pulse width of the negative pulses are 10-1000 ns, and the time interval is 10-1000 ns. The cell membrane permeability and the cell death efficiency can be remarkably improved, and the limitation of the traditional IRE technology is broken through.
Owner:SUZHOU YUANKE MEDICAL EQUIPMENT CO LTD

Polyethylene glycol modified gold-manganese dioxide nanoparticles as well as preparation method and application thereof

The invention discloses a polyethylene glycol modified gold and manganese dioxide nano particle and a preparation method and application thereof, and belongs to the technical field of biological medicine, the polyethylene glycol modified gold and manganese dioxide nano particle (GMCN and PEG) has good biocompatibility under neutral physiological conditions, can relieve tumor hypoxia and increase generation of active oxygen in acidic TME, and has a good anti-tumor effect. The radiotherapy sensitivity is improved; and immune cell death is induced. Meanwhile, a cGAS-STING signal channel can be activated, dendritic cell maturation, macrophage M1 polarization and T cell infiltration are promoted, and the immunosuppression state in TME is counteracted. In addition, the GMCN-coated PEG also has an MR-CT bimodal imaging enhancement function, and integration of diagnosis and treatment is realized. The nano sensitizer disclosed by the invention has huge potential in the aspects of improving the radiotherapy curative effect, remodeling the tumor microenvironment, promoting the anti-tumor immunity, enhancing the biomedical imaging and the like.
Owner:ANHUI PROVINCIAL HOSPITAL

Mitochondria-targeted antioxidants for use in the treatment of cell balloooning-associated diseases, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

Methods and compositions for treating and preventing cell ballooning and other diseases or medical conditions are provided. The diseases or medical conditions are characterized by cell degeneration or cell death as a part of the disease pathogenesis. Cell ballooning is a condition associated with storage of excess fat in the liver. nutritional or biochemical imbalance, damage to mitochondria, ATP depletion, or virus infection. A mitochondrially targeted antioxidant compound is administered to a subject in need thereof, whereby excess fat is metabolized.
Owner:MITOTECH SA

Gamma delta t cell compositions and methods of use

PCT designated stageWO2025190396A1Immunoglobulin superfamilyHydrolasesCIITADeath Receptors
The present disclosure provides genetically modified iPSC-derived γδT cells and their precursors. A double genomic disruption in the suppressor of cytokine signaling 1 (SOCS1) gene and the cytokine-inducible sh2-containing protein (CISH) gene are provided, as is a triple genomic disruption in genes for SOCS1, CISH, and Bcl-2 interacting mediator of cell death (BIM), as is a quadruple genomic disruption in genes for SOCS1, CISH, BIM, and cell surface death receptor (FAS), as is a quintuple genomic disruption in genes for SOCS1, CISH, BIM, β-2-Microglobulin (B2M), and class II transactivator (CIITA), as is a sextuple genomic disruption in genes for SOCS1, CISH, BIM, B2M, CIITA, and FAS. Also provided is genetically modified iPSC-derived γδT cells and their precursors with improved proliferation and tumor killing activity. Also provided are genetically modified iPSC-derived γδT cells and their precursors further comprising CD19 CAR. The present disclosure further provides methods making and using such cells, as well as gene editing systems.
Owner:BEIGENE GUANGZHOU BIOLOGICS MFG CO LTD +1

Green ecological bacteriostatic composite protective mask

The invention discloses a green ecological bacteriostatic composite protective mask in the technical field of protective masks, which comprises an external protective layer, one side of the external protective layer is fixedly connected with a middle sterilizing layer, and one side of the middle sterilizing layer far away from the external protective layer is fixedly connected with an internal skin-friendly layer. The invention provides an efficient antibacterial layer with triple antibacterial effects. Guanidine salt and 1-O-acetyl inula flower lactone containing a sesquiterpene lactone structure are grafted on hydroxy propyl cellulose; sesquiterpene lactone destroys bacterial cell walls and generates bactericidal active oxygen, guanidyl enhances the capacity of capturing bacteria through electrostatic attraction, and the sesquiterpene lactone and guanidyl act together to disturb cell membrane structures and cause cell death; the protective mask can sterilize for a long time, the replacement frequency is reduced, the sesquiterpene lactone can reduce peculiar smell and diminish inflammation, and the comfort level of a user is enhanced; the protection function of the outer layer is enhanced through fat-soluble protein modified polylactic acid, and the structural stability is improved; all the used base materials are green and degradable, and the environmental protection property is excellent.
Owner:DOMINOX TECH (GUANGDONG) CO LTD

Modifying PH of tissue to reverse immunosupression

Embodiments of the present invention include methods of targeting acidosis (low pH) within the tumor microenvironment (TME) through the use of cathodic electrochemical reactions (CER). Low pH is oncogenic by supporting immunosuppression. Electrochemical reactions create local pH effects when a current passes through an electrolytic substrate such as biological tissue. Electrolysis has been used with electroporation (destabilization of the lipid bilayer via an applied electric potential) to increase cell death areas. However, the regulated increase of pH through only the cathode electrode has been ignored as a possible method to alleviate TME acidosis, which could provide substantial immunotherapeutic benefits. Here, ex vivo modeling shows that CERs can intentionally elevate pH to an anti-tumor level and that increased alkalinity promotes activation of naïve macrophages. Embodiments of the invention include pairing CER treatment protocols with existing electric field-based cancer therapies or use as a stand-alone therapy.
Owner:VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY

Cell death detection method and system based on fluorescence technology

The invention relates to the technical field of cell fluorescence analysis, in particular to a cell death detection method and system based on a fluorescence technology, and the method comprises the following steps: collecting fluorescence signal data of cells, carrying out standardization processing, calculating an average value and a standard deviation of each fluorescence channel, carrying out normalization processing on each data point, and calculating a cell death detection result; and standardized fluorescence data is obtained. According to the method, data deviation caused by experimental condition differences is effectively eliminated through normalization processing of fluorescence signal data, in the feature extraction link, features which can best represent cell state changes are screened out through data conversion technologies such as feature value analysis and matrix construction, and the state change of the cells is calculated through calculation of correlation coefficients. The characteristics highly related to cell death are accurately screened, pertinence and effectiveness of the detection model are ensured, parameter optimization and verification of the model pass multiple groups of data tests, the generalization ability of the model is improved, and efficient recognition performance can be maintained under various experimental conditions.
Owner:SHENZHEN MINGJIAN TESTING PROFESSIONAL TECH CO LTD

Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death

PendingUS20260007642A1Organic active ingredientsNervous disorderNeuron cell deathDisease
A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
Owner:CASE WESTERN RESERVE UNIV +3

Antibacterial gel containing flavonoids and preparation method thereof

The invention relates to the technical field of antibacterial gels, and discloses a flavonoid-containing antibacterial gel and a preparation method thereof.The preparation method comprises the steps that carboxymethyl chitosan cross-linked nano sodium hyaluronate, quaternary ammonium salt modified sodium alginate, polyvinyl alcohol, flavonol glycosides, flavanonol and gelatin are added into a stirrer and stirred, and a mixture is obtained; after the reaction is finished, the antibacterial gel containing the flavonoids is obtained. Quaternary ammonium salt groups in the antibacterial gel can destroy cell membranes, enable cellular contents to leak and cause cell death, so that the antibacterial effect is achieved, sodium alginate has more reaction sites, a large amount of quaternary ammonium salt is grafted through reaction, the substitution degree of the quaternary ammonium salt is increased, the antibacterial effect is further improved, and the antibacterial gel has a good antibacterial effect. The sodium alginate and the cardanol have a certain antibacterial effect, so that an antibacterial system is formed by the sodium alginate and the cardanol together.
Owner:LIKE TIMES (WUHAN) BIOTECHNOLOGY CO LTD

Application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency

The invention discloses application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency, belongs to the field of gene editing treatment, and finds that the beta-nicotinamide mononucleotide (NMN) can efficiently inhibit the activity of CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13 systems in a broad-spectrum manner for the first time. The application comprises emergency blocking of off-target effect in gene editing clinical treatment, biological safety prevention and control of a virus vector gene editing system, and CRISPR activity regulation and control of in-vitro non-diagnostic purpose. Experiments show that NMN can inhibit CRISPR-mediated gene damage and cell death in a cell model, the inhibition efficiency in an in-vitro enzyme digestion system reaches 68.7%, and cell growth or transfection efficiency is not affected. The invention provides an innovative solution for safe application of CRISPR (clustered regularly interspaced short palindromic repeats) technology, and the NMN is approved to be taken orally as a health care product, so that the NMN has extremely strong clinical application potential. Compared with the existing CRISPR (clustered regularly interspaced short palindromic repeats)-resistant protein or synthetic small-molecule inhibitor, the NMN has the advantages of endogenous property, high biocompatibility, good oral safety and the like.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Methods of using ATR inhibitors

Disclosed is a method of treating a cancer in a subject using an ATR inhibitor, wherein the cancer has been previously identified as a cancer having a loss of function of STAG2, SETD2, CDK12, ATRIP, REV3L, RAD17, CHTF8, FZR1, RAD51B, RAD51C, RAD51D, PALB2, RNASEH2A, or RNASEH2B. Also disclosed is a method of inducing cell death of an abnormal cancer cell having a loss of function of STAG2, SETD2, CDK12, ATRIP, REV3L, RAD17, CHTF8, FZR1, RAD51B, RAD51C, RAD51D, PALB2, RNASEH2A or RNASEH2B by contacting the cell with an effective amount of an ATR inhibitor.
Owner:REPARE THERAPEUTICS INC

Application of actinomycin D in preparation of ctDNA detection sensitizer

The invention belongs to the technical field of biological medicine, and particularly relates to application of actinomycin D in preparation of a ctDNA detection sensitizer. The invention provides a ctDNA release method based on actinomycin D as an enhancer, which can significantly improve the release level of ctDNA in early small-volume tumors and tiny residual lesions, thereby improving the sensitivity and positive detection rate of liquid biopsy in MRD detection. Under an extremely low dosage, the ActD can generally promote a plurality of human tumor cells to release ctDNA under the condition of not causing obvious cell death, and has good biological safety and adaptability. The method is especially suitable for tiny, biological inert or anatomical position hidden focuses which are difficult to identify by iconography, namely blind area patient groups in disease monitoring, and has a wide clinical application prospect.
Owner:SUN YAT SEN UNIV

TDP1 and eltrombopag in the treatment of myotonic dystrophy type 2

The present invention relates to the use of TDP1 and eltrombopag in the treatment of myotonic dystrophy type 2. The present invention uses a fruit fly model to identify that TDP1 knockdown can effectively rescue neurodegeneration in the CCTG repeat fruit fly model, reduce pigment production block, cell death and ommatidium fusion, and improve motor defects. At the same time, in vitro screening using small molecules found that eltrombopag can be used as a TDP1 inhibitor and can significantly reduce disease cytotoxicity. The present invention provides a new target and pharmacological substance for CCTG repeat expansion diseases in myotonic dystrophy type 2, and expands the medical use of eltrombopag. The present invention provides a new drug with clinical application prospects for the treatment of CCTG repeat expansion diseases in myotonic dystrophy type 2.
Owner:ZHEJIANG HANWEI TECH CO LTD

Nucleic acid molecule with hairpin structure capable of modulating innate immunity and use thereof

PCT designated stage expiredWO2025146858A1VectorsVirus peptidesAntigenProtein kinase binding
The present invention relates to a nucleic acid molecule capable of controlling innate immunity by RNA and, more specifically, to a short duplex hairpin RNA (sdhRNA) that binds to protein kinase R (PKR), which is activated upon recognition of RNA, thereby inhibiting the activity of PKR and suppressing PKR-mediated innate immunity and which, when introduced into the 3'-UTR of mRNA, can increase the expression level of an antigen. The sdhRNA motif according to the present invention inhibits the activity of protein kinase R (PKR) by binding to PKR activated by recognizing RNA. Therefore, when administered into cells in combination with exogenous RNA or as an insert into the 3'-UTR of mRNA, the sdhRNA motif exhibits the effect of reducing RNA-indued PKR activation, mitigating RNA-induced cell death, and downregulating the expression of interferon-stimulated gene (ISG) as well as improving the expression efficiency of a protein encoded by the mRNA. With the effects, the motif is applied to various RNA-based uses, for example, vaccines, in vivo / ex vivo gene therapeutic agents, and the like.
Owner:KOREA ADVANCED INST OF SCI & TECH +1

Application of marine small molecule peptide and active variant thereof in preparation of medicines for treating skin diseases

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY CHINESE ACAD OF SCI

Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection

A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.
Owner:CASE WESTERN RESERVE UNIV

Glucose oxidase compositions as neonatal anticonvulsants

Neonatal epileptic seizures differ from adult epileptic seizures, and many antiepileptic drugs that are effective in adults often fail to treat neonatal epilepsy. Here we show that gluconic acid, a natural organic acid abundant in fruit and honey, and the glucose oxidase enzyme effectively suppress neonatal epilepsy both in vitro and in vivo. Sodium gluconate is demonstrated to suppress epileptiform burst activity in cell culture and protect neurons from kainic acid-induced cell death. Sodium gluconate also suppresses epileptiform burst activity in brain slices in a manner far more effective in neonatal animals than in aged animals. Sodium gluconate suppresses seizure activity in neonatal animals in a manner far more effective than in adult animals. Consistently, in vivo EEG recordings also revealed that sodium gluconate suppresses seizure activity in neonatal animals in a manner far more effective than in adult animals. Mechanistically, sodium gluconate suppresses voltage-dependent CLC‑3 C1 in neuronal cultures and hippocampal slices ‑ Together, these data suggest a new class of antiepileptic drugs, gluconate, that blocks CLC‑3 C1 ‑ The channel effectively suppresses neonatal epileptic seizures.
Owner:THE PENN STATE RES FOUND INC